LEADS BIOLABS-B Shares Shift with HK$364 Million in Custody Transfers, Representing 3.62% of Total

Stock News08-03

Data from the Hong Kong Stock Exchange shows that on July 31, LEADS BIOLABS-B (09887) experienced a notable change in share custody, with a total transfer value of HK$364 million, accounting for 3.62% of the total shares. The company's shareholders transferred 3.1264 million shares to Citibank, while 4.0694 million shares were moved out of China Securities Depository and Clearing Hong Kong.

LEADS BIOLABS-B announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved its self-developed candidate drug, Velixin™ (a PD-L1/4-1BB bispecific antibody Opatisumomab, LBL-024), for a new drug clinical trial application (IND) to treat metastatic colorectal cancer (mCRC). The approved clinical trial is an open-label, multi-center Phase Ib/II study designed to evaluate the safety and efficacy of Velixin™ in combination therapy for mCRC.

This milestone marks a significant step in expanding Velixin™'s indications within gastrointestinal tumors. The company's immunotherapy pipeline has now extended from biliary tract cancer (BTC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC) to colorectal cancer (CRC), a cancer type with highly unmet clinical needs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168072852?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 08:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168072852","market":"sh","top_or_hot":-1,"title":"LEADS BIOLABS-B Shares Shift with HK$364 Million in Custody Transfers, Representing 3.62% of Total","media":"Stock News","content":"<p>Data from the Hong Kong Stock Exchange shows that on July 31, <b>LEADS BIOLABS-B (09887)</b> experienced a notable change in share custody, with a total transfer value of HK$364 million, accounting for 3.62% of the total shares. The company's shareholders transferred 3.1264 million shares to Citibank, while 4.0694 million shares were moved out of China Securities Depository and Clearing Hong Kong.<br><br><b>LEADS BIOLABS-B</b> announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved its self-developed candidate drug, Velixin™ (a PD-L1/4-1BB bispecific antibody Opatisumomab, LBL-024), for a new drug clinical trial application (IND) to treat metastatic colorectal cancer (mCRC). The approved clinical trial is an open-label, multi-center Phase Ib/II study designed to evaluate the safety and efficacy of Velixin™ in combination therapy for mCRC.<br><br>This milestone marks a significant step in expanding Velixin™'s indications within gastrointestinal tumors. The company's immunotherapy pipeline has now extended from biliary tract cancer (BTC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC) to colorectal cancer (CRC), a cancer type with highly unmet clinical needs.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEADS BIOLABS-B Shares Shift with HK$364 Million in Custody Transfers, Representing 3.62% of Total</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEADS BIOLABS-B Shares Shift with HK$364 Million in Custody Transfers, Representing 3.62% of Total\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-03 08:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Data from the Hong Kong Stock Exchange shows that on July 31, <b>LEADS BIOLABS-B (09887)</b> experienced a notable change in share custody, with a total transfer value of HK$364 million, accounting for 3.62% of the total shares. The company's shareholders transferred 3.1264 million shares to Citibank, while 4.0694 million shares were moved out of China Securities Depository and Clearing Hong Kong.<br><br><b>LEADS BIOLABS-B</b> announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved its self-developed candidate drug, Velixin™ (a PD-L1/4-1BB bispecific antibody Opatisumomab, LBL-024), for a new drug clinical trial application (IND) to treat metastatic colorectal cancer (mCRC). The approved clinical trial is an open-label, multi-center Phase Ib/II study designed to evaluate the safety and efficacy of Velixin™ in combination therapy for mCRC.<br><br>This milestone marks a significant step in expanding Velixin™'s indications within gastrointestinal tumors. The company's immunotherapy pipeline has now extended from biliary tract cancer (BTC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC) to colorectal cancer (CRC), a cancer type with highly unmet clinical needs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000252152.HKD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","start_time":0,"source_url":"","article_id":"1168072852","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168072852","pubTimestamp":1785718227,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Data from the Hong Kong Stock Exchange shows that on July 31, LEADS BIOLABS-B (09887) experienced a notable change in share custody, with a total transfer value of HK$364 million, accounting for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161027":"证券","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","BK1161":"生物科技","09887":"维立志博-B","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元"},"translate_title":"LEADS BIOLABS-B 股份转让3.64亿港元，占总数3.62%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1,"09887":1},"content_text":"Data from the Hong Kong Stock Exchange shows that on July 31, LEADS BIOLABS-B (09887) experienced a notable change in share custody, with a total transfer value of HK$364 million, accounting for 3.62% of the total shares. The company's shareholders transferred 3.1264 million shares to Citibank, while 4.0694 million shares were moved out of China Securities Depository and Clearing Hong Kong.LEADS BIOLABS-B announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved its self-developed candidate drug, Velixin™ (a PD-L1/4-1BB bispecific antibody Opatisumomab, LBL-024), for a new drug clinical trial application (IND) to treat metastatic colorectal cancer (mCRC). The approved clinical trial is an open-label, multi-center Phase Ib/II study designed to evaluate the safety and efficacy of Velixin™ in combination therapy for mCRC.This milestone marks a significant step in expanding Velixin™'s indications within gastrointestinal tumors. The company's immunotherapy pipeline has now extended from biliary tract cancer (BTC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC) to colorectal cancer (CRC), a cancer type with highly unmet clinical needs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168072852","isCrawlerRequest":true}